Literature DB >> 10852264

Do lupus disease activity measures detect clinically important change?

P R Fortin1, M Abrahamowicz, A E Clarke, C Neville, R Du Berger, L Fraenkel, M H Liang.   

Abstract

OBJECTIVE: New scales for the clinical assessment of patients with systemic lupus erythematosus (SLE) are valid and reliable, and quantitate disease activity. We assessed the responsiveness to change of 2 widely used standardized multi-item lupus activity measures, the revised Systemic Lupus Activity Measure (SLAM-R) and the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and their ability to detect clinically relevant changes.
METHODS: Ninety-six (96) patients with definite SLE participated in this study. The group mean age was 45.0 (13.7) years, 91% were female, and the mean disease duration was 14.9 (7.5) years. Sociodemographic information, lupus activity (SLAM-R, SLEDAI), and damage were recorded at baseline. At each of the 5 monthly followup visits, the activity measures were repeated and a transition scale asked the physician if their patient's lupus activity had changed. Five different methods were used to compare the responsiveness of the activity measures studied: 1. the effect size; 2. the standardized response mean; 3. the control standardized response mean; 4. the area under the curve of a receiver operating characteristic (ROC) curve; and 5. a new multiple response modeling approach.
RESULTS: Both SLAM-R and SLEDAI are responsive. SLAM-R is consistently, although moderately, more responsive than SLEDAI. All 5 methods of evaluating responsiveness yielded a consistent ranking of disease activity measures.
CONCLUSION: SLAM-R and SLEDAI are responsive measures of lupus activity. SLAM-R appears to be more responsive than SLEDAI.

Entities:  

Mesh:

Year:  2000        PMID: 10852264

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  11 in total

1.  Are indirect utility measures reliable and responsive in rheumatoid arthritis patients?

Authors:  Carlo A Marra; Amir A Rashidi; Daphne Guh; Jacek A Kopec; Michal Abrahamowicz; John M Esdaile; John E Brazier; Paul R Fortin; Aslam H Anis
Journal:  Qual Life Res       Date:  2005-06       Impact factor: 4.147

2.  Sensitivity analyses of four systemic lupus erythematosus disease activity indices in predicting the treatment changes in consecutive visits: a longitudinal study.

Authors:  Alimohammad Fatemi; Ahmad Raeisi; Zahra Sayedbonakdar; Abbas Smiley
Journal:  Clin Rheumatol       Date:  2017-12-18       Impact factor: 2.980

3.  Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time.

Authors:  G S Alarcón; J Calvo-Alén; G McGwin; A G Uribe; S M A Toloza; J M Roseman; M Fernández; B J Fessler; L M Vilá; C Ahn; F K Tan; J D Reveille
Journal:  Ann Rheum Dis       Date:  2006-09       Impact factor: 19.103

4.  Enhanced expression of interferon-inducible protein-10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus.

Authors:  K O Kong; A W Tan; B Y H Thong; T Y Lian; Y K Cheng; C L Teh; E T Koh; H H Chng; W G Law; T C Lau; K P Leong; B P Leung; H S Howe
Journal:  Clin Exp Immunol       Date:  2009-01-23       Impact factor: 4.330

5.  Validation of the systemic lupus erythematosus activity questionnaire in a large observational cohort.

Authors:  Jinoos Yazdany; Edward H Yelin; Pantelis Panopalis; Laura Trupin; Laura Julian; Patricia P Katz
Journal:  Arthritis Rheum       Date:  2008-01-15

6.  Multimodal neurophysiological and psychometric evaluation among patients with systemic lupus erythematosus.

Authors:  Ghaydaa A Shehata; Yasser Mb Elserogy; Hossam Eddin K Ahmad; Mohamed I Abdel-Kareem; Ashraf M Al-Kabeer; Mohamed M Rayan; Mohamed Es Abd El-Baky
Journal:  Int J Gen Med       Date:  2011-04-20

7.  The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients.

Authors:  Chee-Seng Yee; Vernon T Farewell; David A Isenberg; Bridget Griffiths; Lee-Suan Teh; Ian N Bruce; Yasmeen Ahmad; Anisur Rahman; Athiveeraramapandian Prabu; Mohammed Akil; Neil McHugh; Christopher Edwards; David D'Cruz; Munther A Khamashta; Caroline Gordon
Journal:  Rheumatology (Oxford)       Date:  2011-01-18       Impact factor: 7.580

Review 8.  Approaches for estimating minimal clinically important differences in systemic lupus erythematosus.

Authors:  Sharan K Rai; Jinoos Yazdany; Paul R Fortin; J Antonio Aviña-Zubieta
Journal:  Arthritis Res Ther       Date:  2015-06-03       Impact factor: 5.156

9.  Subclinical cerebrovascular cognitive function, and mood changes in patients with systemic lupus erythematosus.

Authors:  Ghaydaa A Shehata; Mohamed I Abdel-Kareem; Abd Ellah N Yassin; Abdel Hamid R El Adl
Journal:  Open Access Rheumatol       Date:  2010-07-03

10.  The BILAG-2004 index is sensitive to change for assessment of SLE disease activity.

Authors:  Chee-Seng Yee; Vernon Farewell; David A Isenberg; Bridget Griffiths; Lee-Suan Teh; Ian N Bruce; Yasmeen Ahmad; Anisur Rahman; Athiveeraramapandian Prabu; Mohammed Akil; Neil McHugh; Christopher Edwards; David D'Cruz; Munther A Khamashta; Peter Maddison; Caroline Gordon
Journal:  Rheumatology (Oxford)       Date:  2009-04-24       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.